Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization

Cancer Research

Volumn 72, Issue 8, 2012, Pages 1953-1963

  Tugues, Sònia ^a   Honjo, Satoshi ^a   Kon̈ig, Christian ^a   Noguer, Oriol ^a   Hedlund, Marie ^a   Botling, Johan ^a   Deschoemaeker, Sofie ^b,c   Wenes, Mathias ^b,c   Rolny, Charlotte ^a   Jahnen Dechent, Wilhelm ^d   Mazzone, Massimiliano ^b,c   Claesson Welsh, Lena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; HISTIDINE RICH GLYCOPROTEIN; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL INFILTRATION; CONTROLLED STUDY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE EXACERBATION; EXTRACELLULAR MATRIX; FIBROSARCOMA; GENE EXPRESSION; GENETIC DISORDER; HUMAN; HUMAN CELL; HYPOXIA; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTIC INFILTRATION; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PERITONEUM MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TARGET CELL; TUMOR BLOOD FLOW; TUMOR ESCAPE; TUMOR NECROSIS; TUMOR VASCULARIZATION; WILD TYPE;

ANIMALS; HUMANS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEINS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84860207059     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2194     Document Type: Article

References (44)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Leite de Oliveira R, Hamm A, Mazzone M. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Mol Aspects Med 2011;32:71-87.
3. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011;364:656-65.
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
5. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
6. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. Inflammation- mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010;29:243-8.
7. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumor progression. Semin Cancer Biol 2008;18:349-55.
8. Squadrito ML, de Palma M. Macrophage regulation of tumor angiogenesis, implications for cancer therapy. Mol Aspect Med 2011;32:123-45.
9. Mantovani A, Sica A. Macrophages, innate immunity, and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-7.
10. Koide T, Foster D, Yoshitake S, Davie EW. Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochemistry 1986;25:2220-5. (Pubitemid 16036040)
11. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011;19:31-44.
12. Poon IK, Patel KK, Davis DS, Parish CR, Hulett MD. Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma. Blood 2011;117:2093-101.
13. Donate F, Juarez JC, Guan X, Shipulina NV, Plunkett ML, Tel-Tsur Z, et al. Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities. Cancer Res 2004;64:5812-7. (Pubitemid 39095581)
14. Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, et al. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res 2002;62:5344-50. (Pubitemid 35024611)
15. Olsson AK, Larsson H, Dixelius J, Johansson I, Lee C, Oellig C, et al. A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res 2004;64:599-605. (Pubitemid 38120899)
16. Karrlander M, Lindberg N, Olofsson T, Kastemar M, Olsson AK, Uhrbom L. Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma. PLoS One 2009;4:e8536.
17. Dixelius J, Olsson AK, Thulin A, Lee C, Johansson I, Claesson-Welsh L. Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein. Cancer Res 2006;66:2089-97.
18. Manderson GA, Martin M, Onnerfjord P, Saxne T, Schmidtchen A, Mollnes TE, et al. Interactions of histidine-rich glycoprotein with immunoglobulins and proteins of the complement system. Mol Immunol 2009;46:3388-98.
19. Chang NS, Leu RW, Rummage JA, Anderson JK, Mole JE. Regulation of macrophage Fc receptor expression and phagocytosis by histidinerich glycoprotein. Immunology 1992;77:532-8. (Pubitemid 23000473)
20. Gorgani NN, Theofilopoulos AN. Contribution of histidine-rich glycoprotein in clearance of immune complexes and apoptotic cells: implications for ameliorating autoimmune diseases. Autoimmunity 2007;40:260-6. (Pubitemid 46845518)
21. Burch MK, Morgan WT. Preferred heme binding sites of histidine-rich glycoprotein. Biochemistry 1985;24:5919-24. (Pubitemid 16203034)
22. Vanwildemeersch M, Olsson AK, Gottfridsson E, Claesson-Welsh L, Lindahl U, Spillmann D. The antiangiogenic His/Pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent manner. J Biol Chem 2006;281:10298-304. (Pubitemid 43864568)
23. Gorgani NN, Parish CR, Easterbrook Smith SB, Altin JG. Histidine-rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes. Biochemistry 1997;36:6653-62. (Pubitemid 27242323)
24. Gorgani NN, Smith BA, Kono DH, Theofilopoulos AN. Histidine-rich glycoprotein binds to DNA and Fc gamma RI and potentiates the ingestion of apoptotic cells by macrophages. J Immunol 2002;169:4745-51. (Pubitemid 35217136)
25. Shannon O, Rydengard V, Schmidtchen A, Morgelin M, Alm P, Sorensen OE, et al. Histidine-rich glycoprotein promotes bacterial entrapment in clots and decreases mortality in a mouse model of sepsis. Blood 2010;116:2365-72.
26. Asjo B, Ivhed I, Gidlund M, Fuerstenberg S, Fenyo EM, Nilsson K, et al. Susceptibility to infection by the human immunodeficiency virus (HIV) correlates with T4 expression in a parental monocytoid cell line and its subclones. Virology 1987;157:359-65. (Pubitemid 17047691)
27. Tsuchida-Straeten N, Ensslen S, Schafer C, Woltje M, Denecke B, Moser M, et al. Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost 2005;3:865-72. (Pubitemid 41632812)
28. Gene Expression Omnibus. http://www.ncbi.nlm.nih.gov/geo/. Cited March 13, 2012.
29. Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, et al. A distinguishing gene signature shared by tumor-infiltrating Tie2- expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009;114:901-14.
30. Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008;14:550-9.
31. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011;89:207-15.
32. De Palma M, Naldini L. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin Cancer Res 2011;17:5226-32.
33. Sarafi MN, Garcia-Zepeda EA, MacLean JA, Charo IF, Luster AD. Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1. J Exp Med 1997;185:99-109. (Pubitemid 27039445)
34. Dejonckheere E, Vandenbroucke RE, Libert C. Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression. Cytokine Growth Factor Rev 2011;22:73-81.
35. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011;11: 750-61.
36. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
37. Ziegler-Heitbrock HW, Thiel E, Futterer A, Herzog V, Wirtz A, Riethmuller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 1988;41:456-61. (Pubitemid 18080805)
38. Raschke WC, Baird S, Ralph P, Nakoinz I. Functional macrophage cell lines transformed by Abelson leukemia virus. Cell 1978;15:261-7. (Pubitemid 9027529)
39. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976;17:565-77.
40. Ringvall M, Thulin A, Zhang L, Cedervall J, Tsuchida-Straeten N, Jahnen-Dechent W, et al. Enhanced platelet activation mediates the accelerated angiogenic switch in mice lacking histidine-rich glycoprotein. PLoS One 2011;6:e14526.
41. Thulin A, Ringvall M, Dimberg A, Kårehed K, Väisänen T, Väisänen MR, et al. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein. Mol Cancer Res 2009;7:1792-802.
42. Fricke I, Gabrilovich DI. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006;35:459-83. (Pubitemid 44266783)
43. Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 2011;23:146-52.
44. Masuda A, Yoshida M, Shiomi H,Morita Y, Kutsumi H, Inokuchi H, et al. Role of Fc Receptors as a therapeutic target. Inflamm Allergy Drug Targets 2009;8:80-6.